| Type 2 Diabetes Mellitus |
1 |
1 |
| Cardiovascular Risk Management |
0 |
0.73 |
| Heart Failure (HF) |
0 |
0.71 |
| Hypertension |
0 |
0.66 |
| Cerebrovascular Accident |
0 |
0.34 |
| Clinical Guidelines |
0 |
0.34 |
| Heart |
0 |
0.34 |
| Sulfonylureas |
0 |
0.34 |
| Washington |
0 |
0.34 |
| Acute Coronary Syndrome |
0 |
0.25 |
| Lipids Management |
0 |
0.25 |
| Blood |
0 |
0.23 |
| Cardiovascular disease |
0 |
0.23 |
| DPP-4 Inhibitors |
0 |
0.23 |
| Generics |
0 |
0.23 |
| Hospital |
0 |
0.23 |
| Massachusetts |
0 |
0.23 |
| Metabolism |
0 |
0.23 |
| Angina Pectoris |
0 |
0.21 |
| Thromboembolism |
0 |
0.21 |
| GLP-1 Receptor Agonist |
0 |
0.19 |
| LDL Cholesterol |
0 |
0.19 |
| Myocardial Infarction (MI) |
0 |
0.13 |
| Antihypertensive Agents |
0 |
0.11 |
| Brachial |
0 |
0.11 |
| Diabetes Research |
0 |
0.11 |
| Endocrinology |
0 |
0.11 |
| Infarction |
0 |
0.11 |
| Injectable Medications |
0 |
0.11 |
| Lipoproteins |
0 |
0.11 |
| Receptors |
0 |
0.11 |
| Stent |
0 |
0.11 |
| Thrombosis |
0 |
0.11 |
| Transient Ischemic Attack (TIA) |
0 |
0.11 |
| Unstable Angina |
0 |
0.11 |